Assertio Therapeutics (ASRT) BidaskScore is downgraded to Strongly Sold

Assertio Therapeutics, Inc.

The BidaskScore of Assertio Therapeutics Inc. ASRTASRT shows that the shares of the company are now ASRTStrongly Bought Strongly Sold by investors.

The BidaskScore of the PharmaceuticalsPharmaceuticals shows that the sector is PharmaceuticalsStrongly Bought Held since April 21.

Here are the BidAskScore of other related companies in the Pharmaceuticals sector:

Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL.

Assertio Therapeutics, Inc.

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.